RxDoctor Payments DataLook up a doctor →

Richard Smalling, MD

Cardiovascular Disease · Houston, TXNPI 1093733321

Payments from drug & device makers

$907,520in general payments, 2019–2025

Across 422 payments — averaging $2150.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$456K
  • Edwards Lifesciences$423K
  • Canon Medical Systems Corporation$20K
  • Medtronic$6K
  • Boston Scientific$931
  • W. L. Gore & Associates, Inc.$578
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$17,14939%
  • Speaking & faculty fees$11,56926%
  • Travel & lodging$5,40012%
  • Food & beverage$9,83822%
  • Other$2821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$907,520 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$114,881
Medicare patients
176
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$132,922
Repatha SureclickEvolocumab55$49,807
JardianceEmpagliflozin36$47,490
BrilintaTicagrelor41$43,596
XareltoRivaroxaban18$16,871
FarxigaDapagliflozin Propanediol15$14,920
EntrestoSacubitril/Valsartan12$10,157
Metoprolol Succinate300$6,760
Repatha SyringeEvolocumab12$6,295
Ezetimibe120$3,794
Torsemide153$3,367
Nifedipine ErNifedipine120$3,303
Amiodarone Hcl46$2,989
Lisinopril224$2,581
Ranolazine ErRanolazine12$2,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$22$58,51656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →